An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat

Christopher M. Peters, Juan Miguel Jimenez-Andrade, Michael A. Kuskowski, Joseph R. Ghilardi, Patrick W Mantyh

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

Paclitaxel (Taxol®) is a frontline antineoplastic agent used to treat a variety of solid tumors including breast, ovarian, or lung cancer. The major dose limiting side effect of paclitaxel is a peripheral sensory neuropathy that can last days to a lifetime. To begin to understand the cellular events that contribute to this neuropathy, we examined a marker of cell injury/regeneration (activating transcription factor 3; ATF3), macrophage hyperplasia/hypertrophy; satellite cell hypertrophy in the dorsal root ganglia (DRG) and sciatic nerve as well as astrocyte and microglial activation within the spinal cord at 1, 4, 6 and 10 days following intravenous infusion of therapeutically relevant doses of paclitaxel. At day 1 post-infusion, there was an up-regulation of ATF3 in a subpopulation of large and small DRG neurons and this up-regulation was present through day 10. In contrast, hypertrophy of DRG satellite cells, hypertrophy and hyperplasia of CD68+ macrophages in the DRG and sciatic nerve, ATF3 expression in S100β+ Schwann cells and increased expression of the microglial marker (CD11b) and the astrocyte marker glial fibrillary acidic protein (GFAP) in the spinal cord were not observed until day 6 post-infusion. The present results demonstrate that using the time points and markers examined, DRG neurons show the first sign of injury which is followed days later by other neuropathological changes in the DRG, peripheral nerve and dorsal horn of the spinal cord. Understanding the cellular changes that generate and maintain this neuropathy may allow the development of mechanism-based therapies to attenuate or block this frequently painful and debilitating condition.

Original languageEnglish (US)
Pages (from-to)46-59
Number of pages14
JournalBrain Research
Volume1168
Issue number1
DOIs
StatePublished - Sep 7 2007
Externally publishedYes

Fingerprint

Spinal Ganglia
Paclitaxel
Peripheral Nerves
Intravenous Administration
Spinal Cord
Pathology
Hypertrophy
Sciatic Nerve
Astrocytes
Hyperplasia
Activating Transcription Factor 3
Up-Regulation
Macrophages
Neurons
Schwann Cells
Glial Fibrillary Acidic Protein
Wounds and Injuries
Peripheral Nervous System Diseases
Intravenous Infusions
Antineoplastic Agents

Keywords

  • Breast cancer
  • Neuropathic pain
  • Neurotoxicity
  • Taxane
  • Vincristine

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Developmental Biology
  • Molecular Biology

Cite this

An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat. / Peters, Christopher M.; Jimenez-Andrade, Juan Miguel; Kuskowski, Michael A.; Ghilardi, Joseph R.; Mantyh, Patrick W.

In: Brain Research, Vol. 1168, No. 1, 07.09.2007, p. 46-59.

Research output: Contribution to journalArticle

Peters, Christopher M. ; Jimenez-Andrade, Juan Miguel ; Kuskowski, Michael A. ; Ghilardi, Joseph R. ; Mantyh, Patrick W. / An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat. In: Brain Research. 2007 ; Vol. 1168, No. 1. pp. 46-59.
@article{88729b2cc80148c3a8fca0ca8e190a85,
title = "An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat",
abstract = "Paclitaxel (Taxol{\circledR}) is a frontline antineoplastic agent used to treat a variety of solid tumors including breast, ovarian, or lung cancer. The major dose limiting side effect of paclitaxel is a peripheral sensory neuropathy that can last days to a lifetime. To begin to understand the cellular events that contribute to this neuropathy, we examined a marker of cell injury/regeneration (activating transcription factor 3; ATF3), macrophage hyperplasia/hypertrophy; satellite cell hypertrophy in the dorsal root ganglia (DRG) and sciatic nerve as well as astrocyte and microglial activation within the spinal cord at 1, 4, 6 and 10 days following intravenous infusion of therapeutically relevant doses of paclitaxel. At day 1 post-infusion, there was an up-regulation of ATF3 in a subpopulation of large and small DRG neurons and this up-regulation was present through day 10. In contrast, hypertrophy of DRG satellite cells, hypertrophy and hyperplasia of CD68+ macrophages in the DRG and sciatic nerve, ATF3 expression in S100β+ Schwann cells and increased expression of the microglial marker (CD11b) and the astrocyte marker glial fibrillary acidic protein (GFAP) in the spinal cord were not observed until day 6 post-infusion. The present results demonstrate that using the time points and markers examined, DRG neurons show the first sign of injury which is followed days later by other neuropathological changes in the DRG, peripheral nerve and dorsal horn of the spinal cord. Understanding the cellular changes that generate and maintain this neuropathy may allow the development of mechanism-based therapies to attenuate or block this frequently painful and debilitating condition.",
keywords = "Breast cancer, Neuropathic pain, Neurotoxicity, Taxane, Vincristine",
author = "Peters, {Christopher M.} and Jimenez-Andrade, {Juan Miguel} and Kuskowski, {Michael A.} and Ghilardi, {Joseph R.} and Mantyh, {Patrick W}",
year = "2007",
month = "9",
day = "7",
doi = "10.1016/j.brainres.2007.06.066",
language = "English (US)",
volume = "1168",
pages = "46--59",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - An evolving cellular pathology occurs in dorsal root ganglia, peripheral nerve and spinal cord following intravenous administration of paclitaxel in the rat

AU - Peters, Christopher M.

AU - Jimenez-Andrade, Juan Miguel

AU - Kuskowski, Michael A.

AU - Ghilardi, Joseph R.

AU - Mantyh, Patrick W

PY - 2007/9/7

Y1 - 2007/9/7

N2 - Paclitaxel (Taxol®) is a frontline antineoplastic agent used to treat a variety of solid tumors including breast, ovarian, or lung cancer. The major dose limiting side effect of paclitaxel is a peripheral sensory neuropathy that can last days to a lifetime. To begin to understand the cellular events that contribute to this neuropathy, we examined a marker of cell injury/regeneration (activating transcription factor 3; ATF3), macrophage hyperplasia/hypertrophy; satellite cell hypertrophy in the dorsal root ganglia (DRG) and sciatic nerve as well as astrocyte and microglial activation within the spinal cord at 1, 4, 6 and 10 days following intravenous infusion of therapeutically relevant doses of paclitaxel. At day 1 post-infusion, there was an up-regulation of ATF3 in a subpopulation of large and small DRG neurons and this up-regulation was present through day 10. In contrast, hypertrophy of DRG satellite cells, hypertrophy and hyperplasia of CD68+ macrophages in the DRG and sciatic nerve, ATF3 expression in S100β+ Schwann cells and increased expression of the microglial marker (CD11b) and the astrocyte marker glial fibrillary acidic protein (GFAP) in the spinal cord were not observed until day 6 post-infusion. The present results demonstrate that using the time points and markers examined, DRG neurons show the first sign of injury which is followed days later by other neuropathological changes in the DRG, peripheral nerve and dorsal horn of the spinal cord. Understanding the cellular changes that generate and maintain this neuropathy may allow the development of mechanism-based therapies to attenuate or block this frequently painful and debilitating condition.

AB - Paclitaxel (Taxol®) is a frontline antineoplastic agent used to treat a variety of solid tumors including breast, ovarian, or lung cancer. The major dose limiting side effect of paclitaxel is a peripheral sensory neuropathy that can last days to a lifetime. To begin to understand the cellular events that contribute to this neuropathy, we examined a marker of cell injury/regeneration (activating transcription factor 3; ATF3), macrophage hyperplasia/hypertrophy; satellite cell hypertrophy in the dorsal root ganglia (DRG) and sciatic nerve as well as astrocyte and microglial activation within the spinal cord at 1, 4, 6 and 10 days following intravenous infusion of therapeutically relevant doses of paclitaxel. At day 1 post-infusion, there was an up-regulation of ATF3 in a subpopulation of large and small DRG neurons and this up-regulation was present through day 10. In contrast, hypertrophy of DRG satellite cells, hypertrophy and hyperplasia of CD68+ macrophages in the DRG and sciatic nerve, ATF3 expression in S100β+ Schwann cells and increased expression of the microglial marker (CD11b) and the astrocyte marker glial fibrillary acidic protein (GFAP) in the spinal cord were not observed until day 6 post-infusion. The present results demonstrate that using the time points and markers examined, DRG neurons show the first sign of injury which is followed days later by other neuropathological changes in the DRG, peripheral nerve and dorsal horn of the spinal cord. Understanding the cellular changes that generate and maintain this neuropathy may allow the development of mechanism-based therapies to attenuate or block this frequently painful and debilitating condition.

KW - Breast cancer

KW - Neuropathic pain

KW - Neurotoxicity

KW - Taxane

KW - Vincristine

UR - http://www.scopus.com/inward/record.url?scp=34548226494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548226494&partnerID=8YFLogxK

U2 - 10.1016/j.brainres.2007.06.066

DO - 10.1016/j.brainres.2007.06.066

M3 - Article

C2 - 17698044

AN - SCOPUS:34548226494

VL - 1168

SP - 46

EP - 59

JO - Brain Research

JF - Brain Research

SN - 0006-8993

IS - 1

ER -